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Abstract
Background: A high prevalence of obstructive sleep apnea syndrome (OSAS) has been reported in severely obese patients
with nonalcoholic fatty liver disease (NAFLD), but few studies have evaluated OSAS in non-morbidly obese NAFLD patients.
Aims: To determine the prevalence of risk for OSAS with or without daytime sleepiness in non-morbidly obese patients with
NAFLD and evaluate the association with the severity of liver damage.
Methods: We considered 159 consecutive patients with histological NAFLD and body mass index (BMI) ,35 Kg/m2, and 80
controls without ultrasonographic steatosis matched for age, sex, and BMI. OSAS risk was determined by positivity for Berlin
questionnaire (BQ), and daytime sleepiness by the Sleepness Epworth Scale (ESS). Liver damage was evaluated according to
the NAFLD activity score.
Results: In NAFLD patients, BQ alone was positive in 39 (25%), ESS in 8 (5%), and both in 13 (8%, OSAS with sleepines); p = ns
vs. controls without steatosis. In NAFLD patients at risk for OSAS with (but not in those without) sleepiness, we observed a
higher prevalence of nonalcoholic steatohepatitis (NASH; 11/13, 85% vs. 72/146, 49%; p = 0.018), and of clinically significant
fibrosis (stage.1; 9/13, 69% vs. 39/146, 27%; p = 0.003). At multivariate logistic regression analysis, OSAS with sleepiness
was strongly associated with NASH and fibrosis.1 independently of known clinical risk factors such as age, gender, BMI,
diabetes, and ALT levels (OR 7.1, 95% c.i. 1.7–51, p = 0.005 and OR 14.0, 95% c.i. 3.5–70, p = 0.0002, respectively).
Conclusions: A proportion of NAFLD patients without severe obesity is at risk for OSAS with daytime sleepiness, which is
associated with the severity of liver damage independently of body mass and other cofactors.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is considered the
hepatic manifestation of the metabolic syndrome related to
systemic insulin resistance [1]. Paralleling the epidemics of obesity,
NAFLD is becoming the most common chronic liver disease in
Western countries, with a prevalence of 30% in the general
population, which ramps up to 60–85% in at risk groups such as
diabetics and obese [2]. NAFLD is characterized by a wide
spectrum of histological liver damage, ranging from simple
steatosis, usually a benign non-progressive condition, to nonalco-
holic steatohepatitis (NASH) with possible evolution to significant
fibrosis (stage .F1), which may evolve to clinically manifest liver
disease, i.e. decompensated cirrhosis and hepatocellular carcinoma
[3]. Although genetic variability is involved, factors explaining the
susceptibility to progressive liver disease related to NAFLD are not
completely understood [4,5].
Obstructive sleep apnea syndrome (OSAS) is characterized by
recurrent and intermittent episodes of hypoxia during sleeping due
to the collapse of upper airways, resulting in fragmentation of sleep
and excessive daytime somnolence [6]. OSAS is relatively frequent
in the general population, but more so in obesity (prevalence
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40%), which represents a major risk factor [7]. Therefore, OSAS
clusters with metabolic syndrome manifestations, including
NAFLD, and is a risk factor for diabetes [8]. OSAS contributes
also to cardiovascular disease independently of classic metabolic
alterations by inducing transient oxygen desaturation and adren-
ergic activation [9].
Evidence supports a role of oxidative stress in the progression
from simple steatosis to progressive NASH [10], and hepatic
ischemia-reperfusion injury related to OSAS may be implicated.
Indeed, in severely obese NAFLD patients, intermittent hypoxia
has been associated with insulin resistance and histological severity
of liver damage [11,12,13]. These data are in line with a possible
causal role of OSAS in the pathogenesis of liver damage in
NAFLD, with potential therapeutic implications [7]. However,
scant data are available on the relationship between OSAS and
liver damage severity in patients with NAFLD without severe
obesity [14,15,16,17], who represent the majority of patients. This
is particularly evident for the relationship between OSAS and
histological features, which is the gold standard for prognostic
assessment [5].
With this in mind, the aim of this study was to evaluate the
relationship between the risk of OSAS, as evaluated by Berlin
questionnaire (BQ) [18], the presence of excessive daytime
sleepiness, assessed by Epworth sleepiness scale (ESS)
[19,20,21,22], and histological liver damage (presence of NASH
and of significant fibrosis) in a series of Italian patients with
NAFLD without morbid obesity.
Materials and Methods
Subjects
We evaluated 180 consecutive patients with clinical diagnosis of
NAFLD aged between 18 and 70 years, with body mass index
(BMI) lower than 35 Kg/m2, who underwent to liver biopsy
between January 2009 and June 2013 at the Metabolic Liver
Diseases service, Fondazione IRCCS Ca’ Granda, for suspected
NASH. Patients presenting with decompensated liver disease were
excluded. OSAS risk was determined within 6 months from
histological evaluation of liver damage. We excluded from the
analyses patients for whom a weight change .2% was observed
between liver biopsy and the compilation of questionnaires
(n = 10), patients with other coexistent liver diseases [23] (n = 5),
and those with an already established diagnosis of OSAS and/or
under continuous positive airway pressure ventilation therapy
(n = 6). Therefore, 159 were considered in the final analysis.
Demographic and clinical features of patients are shown in table 1.
Controls (n = 80) were randomly selected from the 2554
participants in a population study carried out in the Milan area,
whose cross-sectional phase has recently been completed (Phase 1
CAMELIA study, CArdiovascular risk, MEtabolic sindrome,
LIver, and Autoimmune disease). The 1465 subjects with no
ultrasonographic evidence of hepatic steatosis were matched 1:2
with the study patients if they had the same age and gender, and
were in the same body mass category (normal weight, 18.9–
25 Kg/m2; overweight, 25–29.9 Kg/m2; obese, $30 Kg/m2).
Twenty-one (26%) were women, mean age was 51611 years,
BMI 27.664.3 Kg/m2. As stipulated in the CAMELIA study
protocol, all subjects underwent ultrasonographic evaluation of the
liver with assessment of liver steatosis [24] and were administered
the OSAS questionnaires at time of enrollment.
Biochemical data were measured by routine clinical tests.
Insulin resistance was estimated by the Homeostasis Metabolic
Assessment Insulin Resistance index (HOMA-IR) [25]. Diabetes
and impaired fasting glucose were diagnosed according to World
Health organization criteria [26], whereas metabolic syndrome
was defined according to revised ATPIII criteria [27].
Written informed consent was obtained from each patient
included in the study. The study was approved by the Ethical
Committee of the Fondazione IRCCS Ca’ Granda Milano and of
Legnano Hospital (Milano), and it conforms to the principles of
the Declaration of Helsinki.
Liver Histology
Liver biopsies were performed via percutaneous technique.
Assessment of steatosis, inflammation, ballooning, fibrosis and
overall diagnosis of NASH was determined according to the
NASH clinical research network criteria, and the severity of
liver damage was graded and staged according to the NAFLD
activity score (NAS) [28]. All biopsies are evaluated by a single
expert pathologist (MM). The total NAS score represents the
sum of scores for steatosis, lobular inflammation, and balloon-
ing, and ranges from 0 to 8; whereas the hepatic fibrosis stage
ranges from F0 to F4. Clinically significant fibrosis (i.e. at risk of
progression towards clinically manifest liver disease) was defined
as stage .F1 [29].
Assessment of OSAS risk
Patients filled the two clinical questionnaires, BQ and ESS, in
order to identify subjects at high risk for OSAS and the
concomitant presence of daytime sleepiness, respectively, within
6 months from liver biopsy.
The BQ contains 10 questions covering three categories
including: 1) snoring severity (items 1–5), 2) excessive daytime
sleepiness (items 6–9), and 3) history of high blood pressure or
obesity (item 10). The questionnaire also includes information
about age, sex, height and weight. The patient is instructed to
answer the questions in all three categories. The BQ was scored as
previously reported by Netzer et al. [18]. If the individual scores
are positive in at least 2 of the 3 categories, the patient is classified
as being at high risk for OSAS, whereas if the patient scores
positive in only one or none of the categories, then the patient is
deemed to be at low risk for OSA.
The ESS is an eight-item questionnaire that is used to assess the
presence of daytime sleepiness [19]. The questionnaire asks to
respondents to rate from 0 to 3 their sleepiness in eight daily
situations, giving a total score of 0 (no daytime sleepiness) to 24
(the most excessive daytime sleepiness). The cutoff point for
excessive daytime sleepiness is considered to be equal or greater
than 10 [20].
Therefore, we considered patients at high risk for OSAS those
with positive BQ (BQ+), patients at high risk for OSAS and
symptomatic for excessive daytime sleepiness (BQ+, ESS+) those
who resulted positive for both BQ and ESS questionnaires.
Statistical analysis
Variables are reported as mean and standard deviation (SD) or
frequency, as appropriate. The x2 test was used for categorical
variables, and Student t test or ANOVA for continuous variables,
when appropriate, to evaluate the statistical significances. The
association between high risk of OSAS with or without excessive
daytime sleepiness and the presence of NASH and histological
liver damage was evaluated by multivariate logistic regression
analysis analysis adjusted for biologically relevant confounders
associated with NASH at univariate analysis. Differences were
considered significant when p was ,0.05 (two-tailed). Analyses
were carried out by the JMP 10.0 Statistical analysis software
(SAS, Cary, NJ, USA).
OSAS in NAFLD
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Results
Clinical features of study population
Clinical features of 159 non-morbidly obese patients with
histological NAFLD are presented in table 1. They were mostly
middle-aged (mean age 51 years) overweight (mean BMI 27.4)
males (75%). Forty % had metabolic syndrome, and almost one
third diabetes or IFG. Concerning liver damage, patients were
almost equally distributed between NASH and simple steatosis. As
expected (table 1), patients with NASH had higher insulin
resistance, as indicated by higher BMI (p = 0.008), fasting glucose
(p = 0.012), HOMA-IR (p = 0.04), and prevalence of metabolic
syndrome (p = 0.02). Furthermore, they had higher ALT levels
(p = 0.002) and prevalence of clinically significant hepatic fibrosis
(stage .1; p,0.0001).
Prevalence of positivity for OSAS risk scores
The prevalence of positivity for BQ and ESS in patients and
controls without ultrasonographic steatosis is presented in figure 1.
BQ and ESS were both positive in 13 patients (8%, BQ+ESS+, at
high risk for OSAS and symptomatic for daytime sleepiness,
henceforth OSAS with sleepiness), BQ alone was positive in 39
(25%, BQ+ESS2, at high risk for OSAS, but asymptomatic for
daytime sleepiness), while ESS alone was positive in 8 (5%, BQ2
ESS+, at low risk for OSAS, but symptomatic for hypersomno-
lence). Ninety nine patients (62%, BQ2ESS2) were negative for
both questionnaires. Henceforth, we considered 52 BQ+ patients
(33%) as being at high risk for OSAS, while the 13 (5%) BQ+ESS+
patients as at risk for OSAS with symptomatic daytime sleepiness.
The prevalence of positivity for OSAS risk scores in matched
controls without ultrasonographic steatosis was superimposable to
that of patients (46, 58% BQ2ESS2, 25, 31% BQ+ESS2, 4, 5%
BQ2ESS+, 5, 6% BQ+ESS+; p = ns vs. patients; shown in
figure 1).
Effect of body mass on OSAS risk scores
Positivity for OSAS risk scores was influenced by body mass in
patients (p,0.0001): in 37 mildly obese subjects 14 (38%) were
BQ+ESS2 and 9 (24%) BQ+ESS+, in 78 overweight individuals
18 (23%) were BQ+ESS2 and 3 (4%) BQ+ESS+, among 44
normal weight patients 7 (16%) were BQ+ESS2 and 1 (2%) BQ+
ESS+.
The same trend was observed in matched controls without
ultrasonographic steatosis (p = 0.005): in 19 obese subjects 12
(63%) were BQ+ESS2 and 2 (10%) BQ+ESS+, in 39 overweight
individuals 8 (20%) were BQ+ESS2 and 3 (8%) BQ+ESS+,
among 22 normal weight individuals 5 (23%) were BQ+ESS2, but
none was BQ+ESS+ (p = ns vs. patients).
Clinical features of patients at risk for OSAS with or
without sleepiness
Clinical features of patients according to the risk of OSAS and
the presence of daytime sleepiness are presented in table 2. No
differences in gender distribution, age, insulin resistance and
dyslipidemia were observed, but high risk for OSAS risk was
associated with BMI, hypertension, and the metabolic syndrome
(p,0.05). Serum levels of ALT tended to increase only in patients
at risk for OSAS without sleepiness.
Association between OSAS risk and histological severity
of liver damage
The relationship between risk of OSAS with sleepiness (high risk
vs. low risk) and the severity of liver damage is shown in figure 2.
Patients at risk of OSAS with sleepiness had higher prevalence of
both NASH (p= 0.019) and fibrosis stage.1 (p = 0.003). Positivity
for BQ alone (risk of OSAS without sleepiness) was not associated
with increased risk of NASH (20/39, 51%, p=ns vs. BQ2ESS2)
and fibrosis .1 (15/39, 38%, p= ns vs. BQ2ESS2).
The association of risk of OSAS with sleepiness with the severity
of liver damage was evident for each component of the NAS score
Table 1. Demographic and clinical features of 159 non-morbidly obese patients with histological NAFLD subdivided according to
the presence of NASH.
Overall series Simple steatosis NASH p value
N= 159 (100) 83 (52) 76 (48)
Gender F 39 (25) 15 (20) 24 (29) 0.20
Age years 50.8612 50.8612 50.7612 0.98
BMI Kg/m2 27.463.9 26.363.4 28.464.1 0.008
Hypertension 54 (34) 27 (36) 27 (33) 0.73
Fasting glucose mg/dl 101628 96619 107633 0.012
HOMA-IR 5.463.5 3.462.1 7.562.5 0.04
Total cholesterol mg/dl 202641 205638 198645 0.26
HDL cholesterol mg/dl 48613 49613 46613 0.25
Triglycerides mg/dl 143676 134676 151676 0.14
Diabetes or IFG 46 (28) 17 (22) 29 (35) 0.11
Metabolic syndrome 63 (40) 23 (30) 40 (48) 0.02
ALT IU/ml 54630 45625 63632 0.002
GGT IU/ml 82695 76689 886100 0.45
Fibrosis stage .1 48 (30) 7 (9) 41 (49) ,0.0001
Data are shown as Mean 6 SD (% values); according to data distribution; BMI: body mass index; IFG: impaired fasting glucose; HOMA-IR: homeostasis metabolic
assessment insulin resistance index; ALT: alanine aminotransferases; GGT: gamma-glutamyl-transferase.
doi:10.1371/journal.pone.0096349.t001
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(shown in figure 3): steatosis grade (panel A, p = 0.049),
necroinflammation (panel B, p= 0.010), hepatocellular ballooning
(panel C, p = 0.046), and fibrosis stage (panel D, p= 0.0008).
We also performed a sensitivity analysis excluding patients with
cirrhosis (n = 12, 8%), to evaluate the potential confounding effect
of advanced liver disease on daytime hypersomnolence. High risk
of OSAS with sleepiness remained associated with fibrosis stage .
1 (5/9, 56% vs. 31/138, 22%; p= 0.04), nearly associated with
NASH (7/9, 78% vs. 64/138, 46%; p= 0.06), and associated with
steatosis grade (p = 0.04).
At multivariate logistic regression analysis (shown in table 3),
high risk for OSAS with sleepiness was associated with both
NASH (OR 7.13, 95% c.i 1.70–51.30) and fibrosis stage .1 (OR
14.03, 95% c.i. 3.45–70.11) independently of age, gender,
hyperglycemia, BMI, and ALT levels. The presence of NASH
was also independently associated with higher ALT levels, whereas
fibrosis stage .1 with ALT levels and the presence of diabetes or
IGT (table 3).
Discussion
In this study, we evaluated the prevalence of high risk for OSAS
with or without hypersomnolence, as determined by positivity for
BQ and ESS, as compared to that of matched controls without
ultrasonographic steatosis, and the association with histological
liver damage in a series of non-morbidly obese patients with
Figure 1. Prevalence of positivity for BQ alone (BQ+ESS2), ESS alone (BQ2ESS+), and both BQ and ESS (BQ+ESS+) in 159 non-
morbidly obese patients with histological NAFLD and 80 matched controls without ultrasonographic evidence of hepatic steatosis.
P= ns: not significant.
doi:10.1371/journal.pone.0096349.g001
Table 2. Demographic and clinical features of 159 NAFLD patients according to the risk of OSAS with or without daytime
sleepiness.
High risk High risk Lower risk P value
Sleepiness No sleepiness
(BQ+ ESS+) (BQ+ ESS2) (BQ2)
N= 13 (8) 39 (25) 107 (67)
Gender F 3 (23) 14 (36) 22 (21) 0.17
Age years 49.969.2 52.6612.2 50.2611.5 0.49
BMI Kg/m2 31.664.2* 28.964.3* 26.463.5 ,0.0001
Hypertension 5 (38) 23 (59) * 26 (24) 0.0004
Fasting glucose mg/dl 99613 104629 101629 0.73
HOMA-IR 6.063.9 4.062.1 5.962.8 0.74
Total cholesterol mg/dl 200654 207639 200641 0.67
HDL cholesterol mg/dl 46615 49612 47613 0.68
Triglycerides mg/dl 142683 154682 139673 0.57
Diabetes or IFG 5 (38) 16 (41) 26 (24) 0.11
Metabolic syndrome 7 (54) 23 (59) * 33 (31) 0.005
ALT IU/ml 43620 66636* 51628 0.01
GGT IU/ml 75659 103699 75687 0.29
Data are shown as Mean 6 SD (% values) according to data distribution; P value: at ANOVA; *P,0.05 vs. BQ2 (t-test or Chi-square according to data distribution); BMI:
body mass index; HOMA-IR: homeostasis metabolic assessment insulin resistance index; IFG: impaired fasting glucose; ALT: alanine aminotransferases; GGT: gamma-
glutamyl-transferase.
doi:10.1371/journal.pone.0096349.t002
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NAFLD. The study was prompted by previous evidence indicating
that OSAS may be associated with the severity of NASH in
morbidly obese patients [30,31,32], and in subjects with suspected
OSAS [14], and that daytime somnolence has been associated
with increased fatigue and autonomic dysfunction, possibly related
to severe OSAS, in unselected NAFLD patients [33,34].
We found that almost one in ten patients was at high risk for
OSAS with sleepiness, whereas roughly another third of evaluated
subjects was positive for BQ alone, being therefore at risk for
OSAS, but asymptomatic for hypersomnolence. Futhermore,
additional six patients were excluded from the study because of
a previous confirmed diagnosis of OSAS. The prevalence of
positivity for BQ was similar to that reported in a previous study in
non-morbidly obese patients with NAFLD, which however did not
evaluate ESS, which provides information on the presence of
excessive daytime sleepiness [17]. As expected, the prevalence of
OSAS and OSAS with somnolence increased with increasing body
mass, but high risk of OSAS was also detected in some normal
weight individuals.
However, the positivity for OSAS risk scores was not
significantly higher to that of controls from a sample of the
contemporary general population of the same geographical area,
which was carefully matched for age, sex, and, most importantly,
body mass. These data suggest that OSAS risk is linked with
increased body mass, but the association is not influenced by fatty
liver.
High risk for OSAS with sleepiness was associated with NASH
and each component of the NAFLD score reflecting the activity of
the disease, and it was even more strongly associated with the
fibrosis severity, i.e. the stage of liver damage progression. In
contrast, high risk for OSAS without symptomatic hypersomno-
lence was not associated with the severity of liver damage.
Importantly, even if risk of OSAS was linked with BMI, the
association of risk for OSAS with sleepiness with liver damage was
independent of BMI and of the other major clinical confounders,
such as age, gender, the presence of hyperglycemia, and ALT
levels. All in all, results suggest that the association between OSAS
with somnolence and the severity of liver damage cannot simply be
mediated by obesity or by the induction of insulin resistance and
hyperglycemia.
The relationship between symptomatic high risk for OSAS and
liver damage seemed also independent of advanced liver disease,
as patients with decompensated cirrhosis were excluded from the
study, and the association between high risk for OSAS with
sleepiness and steatosis grade and fibrosis stage .1 was
maintained even after exclusion of patients with compensated
Figure 2. Association between high risk for OSAS with
sleepiness (BQ+ESS+) vs. low risk (all other patients) with
histological severity of liver disease (prevalence of NASH and
of clinically significant fibrosis, i.e. stage .1) in 159 non-
morbidly obese patients with histological NAFLD.
doi:10.1371/journal.pone.0096349.g002
Figure 3. Association between high risk for OSAS with sleepiness (BQ+ESS+) vs. low risk (all other patients) with histological
severity of liver disease as determined by components of NAFLD activity score (panel A: steatosis grade, panel B:
necroinflammation, panel C: ballooning, panel D: fibrosis stage) in 159 non-morbidly obese patients with histological NAFLD.
doi:10.1371/journal.pone.0096349.g003
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cirrhosis. Therefore, it seems unlikely that portal hypertension and
hepatic dysfunction [35] account for the association between
daytime somnolence and liver disease progression in the present
study.
All in all, the present findings are consistent with the hypothesis
that tissue hypoxia and reperfusion injury are involved in the
pathogenesis of NASH and may contribute to fibrosis progression
in a subset of NAFLD patients. In line with our data, in
experimental models intermittent hepatic hypoxia favored lipo-
genesis, oxidative damage and inflammation, and activation of
fibrogenesis [11,12,13].
Strengths of this study are represented by the systematic
evaluation of non-morbidly obese patients with NAFLD, who
still represent the majority of NAFLD cases in Italy and Europe
[2,36], and by the availability of liver histology in all patients,
the gold standard for prognostic assessment [5]. Indeed, ALT
levels and other noninvasive biomarkers, which were correlated
with OSAS in previous studies as indices of liver damage
[14,15,16] are insufficiently accurate biomarkers of the severity
of liver disease [5,37].
The main limitation of the study is represented by the lack of
direct assessment of the presence and severity of OSAS by
polysomnography, although BQ has been reported to have good
accuracy in identifying patients at risk in the general population
[18,19,20]. Furthermore, we cannot exclude that ultrasonography
was not sensitive enough to rule out the presence of mild steatosis
in some of high-risk control subjects.
Provided that the relationship between moderate to severe
OSAS, liver damage, and fibrosis is confirmed by polysomono-
graphy in larger series of unselected patients with NAFLD, it
would be worth assessing the effect of treatment with nocturnal
continuous positive airway pressure ventilation on histological liver
damage even in patients who would have otherwise borderline
indication. Indeed, previous studies have suggested that nocturnal
ventilation may improve markers of liver damage in patients with
NAFLD and OSAS [38,39].
Conclusions
In conclusion, a proportion of NAFLD patients without morbid
obesity, which is similar of that of matched subjects from the
general population without ultrasonographic steatosis, is at high
risk for OSAS with excessive daytime sleepiness, as detected by
BQ and ESS combined positivity. High risk for OSAS with (but
not without) sleepiness is independently associated with liver
damage and fibrosis stage. Although the association between
severe OSAS with sleepiness and the histological severity of NASH
awaits confirmation by polysomnography, data suggest that OSAS
may be involved in the pathogenesis of liver disease progression in
NAFLD patients without morbid obesity, with potential thera-
peutic implications.
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